<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="iso-abbrev">Clin. Cancer Res.</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Clinical cancer research : an official journal of the American Association for Cancer Research</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-0432</issn>
        <issn pub-type="epub">1557-3265</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC7124988</article-id>
        <article-id pub-id-type="pmcid-ver">PMC7124988.1</article-id>
        <article-id pub-id-type="pmcaid">7124988</article-id>
        <article-id pub-id-type="pmcaiid">7124988</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1547507</article-id>
        <article-id pub-id-type="pmid">31871300</article-id>
        <article-id pub-id-type="doi">10.1158/1078-0432.CCR-19-3165</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1547507</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1547507</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Rosen</surname>
              <given-names initials="EY">Ezra Y.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Goldman</surname>
              <given-names initials="DA">Debra A.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hechtman</surname>
              <given-names initials="JF">Jaclyn F.</given-names>
            </name>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Benayed</surname>
              <given-names initials="R">Ryma</given-names>
            </name>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schram</surname>
              <given-names initials="AM">Alison M</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Cocco</surname>
              <given-names initials="E">Emiliano</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Shifman</surname>
              <given-names initials="S">Sophie</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Gong</surname>
              <given-names initials="Y">Yixiao</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kundra</surname>
              <given-names initials="R">Ritika</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solomon</surname>
              <given-names initials="JP">James P.</given-names>
            </name>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bardelli</surname>
              <given-names initials="A">Alberto</given-names>
            </name>
            <xref ref-type="aff" rid="A7">7</xref>
            <xref ref-type="aff" rid="A8">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Scaltriti</surname>
              <given-names initials="M">Maurizio</given-names>
            </name>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Drilon</surname>
              <given-names initials="A">Alexander</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Iasonos</surname>
              <given-names initials="A">Alexia</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Taylor</surname>
              <given-names initials="BS">Barry S.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A4">4</xref>
            <xref ref-type="aff" rid="A5">5</xref>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hyman</surname>
              <given-names initials="DM">David M.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1.</label>Department of Medicine, Memorial Sloan Kettering, New York, USA</aff>
        <aff id="A2"><label>2.</label>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering, New York, USA</aff>
        <aff id="A3"><label>3.</label>Department of Pathology, Memorial Sloan Kettering, New York, USA</aff>
        <aff id="A4"><label>4.</label>Weill Cornell Medical College, New York, USA</aff>
        <aff id="A5"><label>5.</label>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering, New York, USA</aff>
        <aff id="A6"><label>6.</label>Marie-Jos√©e and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering, New York, USA</aff>
        <aff id="A7"><label>7.</label>Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy</aff>
        <aff id="A8"><label>8.</label>Department of Oncology, University of Torino, Candiolo, Italy</aff>
        <author-notes>
          <corresp id="CR1"><bold>Correspondence:</bold> David M Hyman, MD, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, <email>hymand@mskcc.org</email>, Phone: (646) 888-4544</corresp>
          <fn fn-type="COI-statement" id="FN1">
            <p id="P35">Conflicts of Interest</p>
            <p id="P36">Ezra Y. Rosen: Research Support, Bayer</p>
            <p id="P37">Debra Goldman owns stock in Johnson and Johnson</p>
            <p id="P38">Jaclyn F. Hechtman has received honoraria from Cor2Ed, WebMD, and Axiom Healthcare Strategies as well as research funding from Bayer, Loxo Oncology, and Boehringer Ingelheim.</p>
            <p id="P39">Ryma Benayed: has received a research grant from Archer</p>
            <p id="P40">Alison Schram: None</p>
            <p id="P41">Emiliano Cocco: None</p>
            <p id="P42">Sophie Shifman: None</p>
            <p id="P43">Yixiao Gong: None</p>
            <p id="P44">Ritika Kundra: None</p>
            <p id="P45">James P. Solomon: None</p>
            <p id="P46">Alberto Bardelli: None</p>
            <p id="P47">Maurizio Scaltriti: has received research funds from Puma Biotechnology, Daiichi-Sankio, Immunomedics, Targimmune and Menarini Ricerche, is a cofounder of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://Medendi.org">Medendi.org</ext-link> and is on the advisory board of the Bioscience Institute and Menarini Ricerche.</p>
            <p id="P48">Alexander Drilon reports honoraria from Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines</p>
            <p id="P49">Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences,</p>
            <p id="P50">Verastem, MORE Health, Abbvie; royalties from Wolters Kluwer</p>
            <p id="P51">Alexia Iasonos receives compensation and consulting fees from Brightpath (DSMC), Mylan (DSMC) and Intelligencia</p>
            <p id="P52">Barry S. Taylor reports receiving honoraria and research funding from Genentech.</p>
            <p id="P53">David M. Hyman: Paid consulting: Chugai, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Genentech/Roche, Fount Therapeutics. Research grants: AstraZeneca, Puma Biotechnology, Loxo Oncology, Bayer</p>
          </fn>
        </author-notes>
        <pub-date pub-type="epub">
          <day>23</day>
          <month>12</month>
          <year>2019</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <day>01</day>
          <month>4</month>
          <year>2020</year>
        </pub-date>
        <volume>26</volume>
        <issue>7</issue>
        <issue-id pub-id-type="pmc-issue-id">355330</issue-id>
        <fpage>1624</fpage>
        <lpage>1632</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>08</day>
              <month>01</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>10</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>10</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-06-16 14:25:12.730">
              <day>16</day>
              <month>06</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1547507.pdf"/>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Background:</title>
            <p id="P1">TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion-positive cancers and consequently are now an established standard of care. Little is known, however, about the demographics, outcomes, response to alternative standard therapies, or genomic characteristics of TRK fusion-positive cancers.</p>
          </sec>
          <sec id="S2">
            <title>Methods:</title>
            <p id="P2">Utilizing a center-wide screening program involving more than 26,000 prospectively sequenced patients, genomic and clinical data from all cases with TRK fusions were extracted. An integrated analysis was performed of genomic, therapeutic, and phenomic outcomes.</p>
          </sec>
          <sec id="S3">
            <title>Results:</title>
            <p id="P3">We identified 76 cases with confirmed TRK fusions (0.28% overall prevalence) involving 48 unique rearrangements and 17 cancer types. The presence of a TRK fusion was associated with depletion of concurrent oncogenic drivers (p&lt;0.001) and lower TMB (p&lt;0.001), with the exception of colorectal cancer where TRK fusions co-occur with microsatellite instability (MSI-H). Longitudinal profiling in a subset of patients indicated that TRK fusions were present in all sampled timepoints in 82% (14/17) of cases. PFS on first-line therapy, excluding TRK inhibitors, administered for advanced disease was 9.6 months (95% CI: 4.8-13.2). The best ORR achieved with chemotherapy containing-regimens across all lines of therapy was 63% (95% CI: 41-81). Among 12 patients treated with checkpoint inhibitors, an MSI-H colorectal patient had the only observed response.</p>
          </sec>
          <sec id="S4">
            <title>Conclusion:</title>
            <p id="P4">TRK fusion-positive cancers can respond to alternative standards of care, although efficacy of immunotherapy in the absence of other predictive biomarkers (MSI-H) appears limited. TRK fusions are present in tumors with simple genomes lacking in concurrent drivers that may partially explain the tumor-agnostic efficacy of TRK inhibitors.</p>
          </sec>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
